0QAV.L - Nanobiotix SA Stock Price & Dividend Safety Sector: Healthcare | Exchange: London Stock Exchange Current Price & Safety Score Price: 28.10 EUR StockBonds Safety Grade: Altman Z-Score (Bankruptcy Risk): 4.83 StockBond Score: 0.00 Company Description Nanobiotix SA operates as a clinicalstage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs Its lead product candidate is NBTXR3 a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma head and neck cancers liver cancers prostate cancer pancreatic cancer esophageal cancer rectal cancer and nonsmall cell lung cancer The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China South Korea Singapore and Thailand Nanobiotix SA was incorporated in 2003 and is based in Paris France